Kinnate Biopharma Inc.
NASDAQ: KNTE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Nima Farzan
- Employees
- 84
- Headquarters
- San Francisco, United States
- IPO year
- 2020
- Market cap
- $125.0M
- Website
- https://www.kinnate.com
Loading KNTE…
Loading profile data…Frequently asked questions about KNTE
What does Kinnate Biopharma Inc. (KNTE) do?
Kinnate Biopharma Inc. is a U.S.-based biopharmaceutical company primarily focused on identifying and advancing small-molecule drugs that target kinase enzymes to treat cancers defined by specific genetic markers. The company's product pipeline includes: KIN-2787: An inhibitor of rapidly accelerated fibrosarcoma (RAF), currently being developed...
Where does KNTE trade?
Kinnate Biopharma Inc. (KNTE) trades on the NASDAQ Global Select.
What sector is KNTE in?
Kinnate Biopharma Inc. (KNTE) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Kinnate Biopharma Inc.?
Nima Farzan is the chief executive officer of Kinnate Biopharma Inc. (KNTE).
Where is Kinnate Biopharma Inc. headquartered?
Kinnate Biopharma Inc. is headquartered in United States.
Does KNTE pay a dividend?
Kinnate Biopharma Inc. (KNTE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did KNTE go public?
Kinnate Biopharma Inc. (KNTE) completed its initial public offering in 2020.